MedTrace Logo

Young Plasma Transfusions for Progressive Supranuclear Palsy

NCT02460731 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-08-11

No results posted yet for this study

Summary

This is a phase 1, multi-center, open-label study of the safety, tolerability, pharmacodynamics, and preliminary efficacy of young (\<30 years of age) healthy male donor plasma transfusions in patients with PSP. Up to 10 subjects will receive once monthly 4-unit transfusions of young healthy male donor plasma for 6 months.

Conditions

Interventions

BIOLOGICAL

Fresh Frozen Plasma

Fresh Frozen Plasma \[young (\<30 years of age) healthy male donors\] Solution for intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Richard Tsai, MD, MBA · University of California, San Francisco Memory and Aging Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02460731 on ClinicalTrials.gov